Difference between revisions of "Non-small cell lung cancer, HER2-mutated"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 1: | Line 1: | ||
| + | <span id="BackToTop"></span> | ||
| + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | ||
| + | [[#top|Back to Top]] | ||
| + | </div> | ||
{{#lst:Section editor transclusions|nsclc}} | {{#lst:Section editor transclusions|nsclc}} | ||
Note: these are regimens tested in biomarker-specific populations, please see the '''[[Non-small cell lung cancer|main NSCLC page]]''' for other regimens. | Note: these are regimens tested in biomarker-specific populations, please see the '''[[Non-small cell lung cancer|main NSCLC page]]''' for other regimens. | ||
| Line 9: | Line 13: | ||
=Metastatic disease, all lines of therapy= | =Metastatic disease, all lines of therapy= | ||
==Trastuzumab deruxtecan monotherapy {{#subobject:7hg71v|Regimen=1}}== | ==Trastuzumab deruxtecan monotherapy {{#subobject:7hg71v|Regimen=1}}== | ||
| + | ===Regimen variant #1, 5.4 mg/kg {{#subobject:f3hug9|Variant=1}}=== | ||
| + | {| class="wikitable sortable" style="color:white; background-color:#404040" | ||
| + | |<small>'''FDA-recommended dose'''</small> | ||
| + | |- | ||
| + | |} | ||
| + | {| class="wikitable" style="width: 60%; text-align:center;" | ||
| + | !style="width: 33%"|Study | ||
| + | !style="width: 33%"|Years of enrollment | ||
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | |- | ||
| + | |Awaiting publication (DESTINY-Lung02) | ||
| + | |2021-ongoing | ||
| + | |style="background-color:#91cf61"|Phase 2 (RT) | ||
| + | |- | ||
| + | |} | ||
| + | ====Biomarker eligibility criteria==== | ||
| + | *HER2 mutations | ||
| + | ====Antibody-drug conjugate therapy==== | ||
| + | |||
| + | *[[Trastuzumab deruxtecan (Enhertu)]] 5.4 mg/kg IV once on day 1 | ||
| + | |||
| + | '''21-day cycles''' | ||
| − | ===Regimen {{#subobject:f3eig9|Variant=1}}=== | + | ===Regimen variant #2, 6.4 mg/kg {{#subobject:f3eig9|Variant=1}}=== |
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" | ||
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
| Line 18: | Line 44: | ||
|[https://doi.org/10.1056/nejmoa2112431 Li et al. 2021 (DESTINY-Lung01)] | |[https://doi.org/10.1056/nejmoa2112431 Li et al. 2021 (DESTINY-Lung01)] | ||
|2018-2020 | |2018-2020 | ||
| + | |style="background-color:#91cf61"|Phase 2 | ||
| + | |- | ||
| + | |Awaiting publication (DESTINY-Lung02) | ||
| + | |2021-ongoing | ||
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
| Line 31: | Line 61: | ||
===References=== | ===References=== | ||
#'''DESTINY-Lung01:''' Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. [https://doi.org/10.1056/nejmoa2112431 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/34534430/ PubMed] NCT03505710 | #'''DESTINY-Lung01:''' Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. [https://doi.org/10.1056/nejmoa2112431 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/34534430/ PubMed] NCT03505710 | ||
| + | #'''DESTINY-Lung02:''' NCT04644237 | ||
[[Category:Non-small cell lung cancer regimens]] | [[Category:Non-small cell lung cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Non-small cell lung cancers]] | [[Category:Non-small cell lung cancers]] | ||
Revision as of 23:19, 11 August 2022
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
4 variants on this page
|
Metastatic disease, all lines of therapy
Trastuzumab deruxtecan monotherapy
Regimen variant #1, 5.4 mg/kg
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Awaiting publication (DESTINY-Lung02) | 2021-ongoing | Phase 2 (RT) |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 5.4 mg/kg IV once on day 1
21-day cycles
Regimen variant #2, 6.4 mg/kg
| Study | Years of enrollment | Evidence |
|---|---|---|
| Li et al. 2021 (DESTINY-Lung01) | 2018-2020 | Phase 2 |
| Awaiting publication (DESTINY-Lung02) | 2021-ongoing | Phase 2 |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 6.4 mg/kg IV once on day 1
21-day cycles
References
- DESTINY-Lung01: Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. link to original article contains verified protocol PubMed NCT03505710
- DESTINY-Lung02: NCT04644237